Q&A

Examining The Emergence Of Unit- & Bi-Dose Nasal Sprays

Source: Catalent
GettyImages-952793068-inhalation-nasal spray

Molecules that are limited by a slow onset of action, a suboptimal side-effect profile, or a complicated administration process, may be good candidates for adaptation to a unit- or bi-dose nasal delivery format. This is especially true for drugs targeting the central nervous system (CNS). Established molecules may also benefit from shorter development timelines and regulatory review cycles.

Nasal spray administration of medicine offers advantages over oral and intravenous (IV) delivery. Catalent’s Andrew Samuelsson, Craig Davies-Cutting and Tom Clark discuss the advantages and opportunities of adopting unit- and bi-dose nasal delivery technology.

VIEW THE Q&A!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma